DermTech to Present at Upcoming Investor Conferences
LA JOLLA, Calif.--(BUSINESS WIRE)--Nov 6, 2019--
DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced that company management is scheduled to participate at the following upcoming investor conferences:
DermTech is a leader in the new category of medicine, precision dermatology. DermTech’s mission is to transform the practice of dermatology through more accurate diagnosis and treatment, and the elimination of unnecessary surgery, leading to improved patient care and lower costs. DermTech provides genomic analysis of skin samples collected non-invasively using an adhesive patch rather than a scalpel. DermTech markets and develops products that facilitate the early detection of skin cancers, assess inflammatory diseases, and customize drug treatments. For additional information on DermTech, please visit DermTech’s investor relations site at: www.dermtech.com.
View source version on businesswire.com:https://www.businesswire.com/news/home/20191106005877/en/
CONTACT: Company Contact:
Westwicke, an ICR company
Caroline Corner, PhD
KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA NEW YORK
INDUSTRY KEYWORD: HEALTH SURGERY OTHER HEALTH MEDICAL DEVICES
SOURCE: DermTech, Inc.
Copyright Business Wire 2019.
PUB: 11/06/2019 02:28 PM/DISC: 11/06/2019 02:28 PM